Out of stock

This item is currently unavailable

Out of stock for 21 days. Get on the list — one email the moment it's back.

Out of stock 21 days · last price £200

Myelodysplastic Syndromes (MDS): Risk Factors, Treatment & Prognosis

Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 70 days · 70 data points (no recent data)

Historical
Generating forecast…
£200.00 £190.00 £194.00 £198.00 £202.00 £206.00 £210.00 25 July 2026 11 August 2026 28 August 2026 14 September 2026 02 October 2026
View at Amazon ↗
Out of stock

Price data last checked 21 day(s) ago - will refresh soon

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 70 days • 1 price levels

Days at Price
70 days 0 18 35 53 70 £200 Days at Price

Price Analysis

Most common price: £200 (70 days, 100.0%)

Price range: £200 - £200

Price levels: 1 different prices over 70 days

Description
Myelodysplastic syndrome (MDS) is a family of clonal haematopoietic stem cells disorders characterized by dysplasia, ineffective hematopoiesis and susceptibility to transformation to Acute Myeloblastic Leukaemia (AML) that are shown to be strikingly refractory to current therapeutic modalities. The first chapter of this book provides a detailed review of the risk factors, treatment options and prognosis of MDS. Chapter two studies the inflammatory and autoimmune nature of MDS. Chapter three discusses the pathogenesis of 5q-syndrome. Chapter four examines the genetic mutations identified in MDS and their significance. Chapter five reviews different prognostic factors and stratifications of risk in Argentinean patients with MDS. Chapter six discusses epigenetics and epigenetic therapy. Chapter seven introduces mild oral chemotherapy treatments for elderly patients with a higher-risk myelodyspastic syndrome. Chapter eight discusses lenalidomide treatment in lower risk myelodysplastic syndromes. Chapter nine analyzes the old and new-integrating prognostic models and mutational advances with epigenetic and cellular therapies for MDS. The last chapter studies the entropy evaluation of bone marrow biopsies in MDS.

Product Specifications
Format
hardcover
ASIN
1634843290
Category
Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine > Haematology
Domain
Amazon UK
Release Date
01 January 2016
Listed Since
27 November 2015

Barcode

No barcode data available